Alembic Pharmaceuticals Share Price Target 2026 Analyst Forecast Bull and Bear Case

The Alembic Pharmaceuticals share price target 2026 is Rs 885, implying approximately 20 percent upside from the current market price of Rs 737.75 (NSE: APLLTD). With Q4 FY26 results released in 2026 and Pharmaceutical Generics and APIs sector tailwinds in focus, the Rs 885 price objective is supported by the FY27 earnings recovery thesis.

Alembic Pharmaceuticals (NSE: APLLTD) is a Pharmaceutical Generics and APIs company trading at Rs 737.75 with a market capitalisation of Rs 13,902 crore. Analysts have set the Alembic Pharmaceuticals share price target at Rs 885 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast for Alembic Pharmaceuticals including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

Alembic Pharmaceuticals Share Price Target 2026: Key Takeaways

• Alembic Pharmaceuticals share price target 2026: Rs 885 (20% upside from CMP Rs 737.75)
• Bull case: Rs 1,050 | Bear case: Rs 590
• Ticker: APLLTD | Sector: Pharmaceutical Generics and APIs | MCap: Rs 13,902 crore
• 52W range: Rs 510 to Rs 1,211 | PE: 18x
• Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
• Key risk: FY27 earnings miss or FII outflows from Indian equities

Alembic Pharmaceuticals Company Overview

Alembic Pharmaceuticals (NSE: APLLTD) is a Vadodara-based R&D-driven pharmaceutical company manufacturing specialty generics, APIs, and branded formulations for the US, India, and RoW markets, with FY26 US generic approvals accelerating and API export growing on China-plus-one sourcing. At CMP Rs 737.75 against a 52 week range of Rs 510 to Rs 1,211, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 13,902 crore with trailing PE of 18x. Compared to peers in pharma like Sun Pharma and Torrent Pharmaceuticals, Alembic Pharmaceuticals is positioned as a potential re-rating candidate toward the Rs 885 price objective on FY27 earnings delivery.

Why Is the Alembic Pharmaceuticals Share Price Target Set at Rs 885 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Alembic Pharmaceuticals share price target of Rs 885 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for a re-rating from CMP Rs 737.75. Until FY27 PAT delivery is confirmed, the Rs 885 objective represents a base case with execution risk attached.

Structural Sector Tailwinds in Pharmaceutical Generics and APIs

The Pharmaceutical Generics and APIs sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Alembic Pharmaceuticals’s market position among peers in pharma like Sun Pharma and Torrent Pharmaceuticals creates a structural growth runway. Sustained sector outperformance is one of the key conditions for the Rs 1,050 bull case to materialise, making sector monitoring essential for investors tracking the stock.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs across sectors and stimulating end market demand. For Alembic Pharmaceuticals, lower interest costs improve the EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 885 analyst consensus in 2026.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a favourable policy backdrop for Alembic Pharmaceuticals’s Pharmaceutical Generics and APIs operations. Policy support increases the probability of Alembic Pharmaceuticals achieving its FY27 earnings targets, supporting the Rs 885 price objective.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 18x PE, Alembic Pharmaceuticals is positioned as a beneficiary of institutional reallocation into the Pharmaceutical Generics and APIs sector, providing a tailwind toward the Rs 1,050 bull case.

Alembic Pharmaceuticals Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Alembic Pharmaceuticals Share Price Target

Near-term support for Alembic Pharmaceuticals is anchored close to the 52 week low of Rs 510. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors eyeing a near-term entry can use the 52 week low as a reference while awaiting the FY27 earnings confirmation that would support the full Rs 885 objective.

12-Month Alembic Pharmaceuticals Share Price Target 2026

The 12-month Alembic Pharmaceuticals share price target 2026 is Rs 885, implying approximately 20 percent upside from CMP Rs 737.75. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows into the Pharmaceutical Generics and APIs sector. Track live price on NSE under ticker APLLTD.

Long Term Alembic Pharmaceuticals Share Price Target: FY27 to FY28

The long term Alembic Pharmaceuticals share price target for FY27 to FY28 is Rs 1,050 in the bull case. Full earnings delivery, re-rating toward higher peer multiples among peers in pharma like Sun Pharma and Torrent Pharmaceuticals, and sustained institutional buying are the three conditions needed to reach Rs 1,050 over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Alembic Pharmaceuticals in 2026

Bull Case Alembic Pharmaceuticals Share Price Target: Rs 1,050

The bull case Alembic Pharmaceuticals share price target of Rs 1,050 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Generics and APIs tailwinds accelerate, and FII flows return strongly to Indian equities. Under this scenario, Alembic Pharmaceuticals re-rates toward higher peer multiples, making Rs 1,050 achievable within FY28, representing approximately 45 percent upside from the current CMP of Rs 737.75.

Bear Case Alembic Pharmaceuticals Share Price Target: Rs 590

The bear case Alembic Pharmaceuticals share price target of Rs 590 materialises if FY27 earnings disappoint or FII outflows depress the broader market. Under this scenario, the stock risks testing 52 week low support near Rs 510, and investors should reassess the thesis before deploying additional capital.

Key Risks That Could Derail the Alembic Pharmaceuticals 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions triggered by the US reciprocal tariff announcement in 2026 have reduced FII risk appetite for Indian equities. A global demand slowdown or escalation in trade tensions remains a prominent macro risk to the Alembic Pharmaceuticals share price target of Rs 885 and could push the stock toward the bear case of Rs 590.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress multiples. This is the most direct company-specific risk to the Rs 885 analyst price objective. Investors should monitor quarterly results and management commentary, especially signals about demand environment, pricing power, and margin compression in Pharmaceutical Generics and APIs.

Competitive Intensity Among Pharmaceutical Generics and APIs Peers

Intensifying competition from peers in pharma like Sun Pharma and Torrent Pharmaceuticals could compress Alembic Pharmaceuticals’s market share and pricing power over the medium term. This structural risk must be weighed when assessing how defensible the earnings trajectory is that underpins the Rs 885 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. For smaller market cap stocks, liquidity constraints can amplify drawdowns. Investors should size positions carefully and maintain stop losses to protect capital if broader market de-rating continues.

How to Invest in Alembic Pharmaceuticals

Check the Univest Screener for live data

Before considering any investment based on the Alembic Pharmaceuticals share price target of Rs 885, review the company’s Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, operating margin trends, debt levels, and management commentary on Pharmaceutical Generics and APIs sector demand and competition.

Open a Demat and trading account with a SEBI registered stockbroker to trade Alembic Pharmaceuticals (NSE: APLLTD) with regulatory protection. Before executing any order, study the competitive landscape among peers in pharma like Sun Pharma and Torrent Pharmaceuticals to assess whether Alembic Pharmaceuticals’s competitive position justifies the Rs 885 valuation.

Plan your entry using the 52 week low of Rs 510 as a key support reference. A confirmed FY27 earnings uptick combined with positive guidance would validate the entry case. Always set a pre-defined stop loss below the 52 week low to limit downside.

Maintain position sizing discipline. Restrict any single stock to 3 to 5 percent of your total equity portfolio, especially in the Pharmaceutical Generics and APIs space where sectoral cycles can amplify volatility beyond initial expectations.

Always consult a SEBI registered financial advisor before making investment decisions based on any analyst price target or market commentary. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Alembic Pharmaceuticals’s live share price and receive daily stock recommendations from SEBI registered analysts.

FAQs on Alembic Pharmaceuticals Share Price Target 2026

What is the Alembic Pharmaceuticals share price target for 2026?

Ans. The Alembic Pharmaceuticals share price target 2026 is Rs 885, implying approximately 20 percent upside from CMP Rs 737.75. The bull case target is Rs 1,050 and the bear case is Rs 590.

What was the Alembic Pharmaceuticals share price target for 2025?

Ans. The 2025 price objective for Alembic Pharmaceuticals was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 885, reflecting FY27 growth potential from the current CMP of Rs 737.75.

Is Alembic Pharmaceuticals a good investment at Rs 737.75?

Ans. At Rs 737.75, Alembic Pharmaceuticals offers potential upside toward Rs 885 if FY27 earnings recover as projected. Whether this represents a good entry depends on individual risk tolerance and portfolio goals. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Alembic Pharmaceuticals share price target 2026?

Ans. Key risks to the Alembic Pharmaceuticals share price target of Rs 885 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Generics and APIs. Monitoring quarterly results and management guidance is essential.

What is the 52 week high and low of Alembic Pharmaceuticals?

Ans. The 52 week high of Alembic Pharmaceuticals is Rs 1,211 and the 52 week low is Rs 510. At CMP Rs 737.75, the stock is trading below its 52 week high and offers upside toward the Rs 885 analyst price objective.

What are the main growth catalysts for Alembic Pharmaceuticals in 2026?

Ans. Primary growth catalysts for Alembic Pharmaceuticals in 2026 include FY27 PAT recovery, Pharmaceutical Generics and APIs sector tailwinds, RBI rate cuts reducing cost of capital, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Alembic Pharmaceuticals compare to its peers?

Ans. Alembic Pharmaceuticals operates in Pharmaceutical Generics and APIs alongside peers in pharma like Sun Pharma and Torrent Pharmaceuticals. At CMP Rs 737.75 with MCap Rs 13,902 crore, the company is positioned as a potential re-rating candidate toward the Alembic Pharmaceuticals share price target of Rs 885 on FY27 earnings delivery.

What is the Alembic Pharmaceuticals share price target for 2027?

Ans. The long-term Alembic Pharmaceuticals share price target for FY27 to FY28 is Rs 1,050 in the bull case, assuming continued earnings growth, sector re-rating, and sustained FII inflows into Indian equities. Consult a SEBI registered financial advisor for personalised guidance.